Background Recent NICE Guidelines have emphasized the need to have in place by 2007 the capability of offering screening to all women in the first trimester using a combination of maternal age with the ultrasound marker nuchal translucency thickness (NT) and the maternal serum biochemical markers free b-hCG and pregnancy-associated plasma protein-A (PAPP-A). Laboratories will therefore need to consider how to introduce the biochemical component of screening. With the recent launch of these assays on the DPC Immulite 2000 platform, it is appropriate and timely to investigate their clinical and analytical performance on a high throughput immunoassay analyser.
Introduction
In recent years there has been a growing interest in moving screening for Down's syndrome into the ¢rst trimester. At this time, screening can be carried out using a combination of maternal age with the ultrasound marker nuchal translucency thickness (NT) and the maternal serum biochemical markers free b-hCG and pregnancy-associated plasma protein-A (PAPP-A). Retrospective studies have suggested that screening at 11--14 weeks using such a combination will allow detection rates of 89% at a 5% false-positive rate for Down's syndrome, 1 while at the same time also identifying 90% of other major chromosomal aneuploidies for an additional 1% false-positive rate. 2--6 In prospective screening practice, such predictions have been largely con¢rmed in routine screening. 7--10 Recently, the NICE Guidelines for Antenatal Care 11 and the antenatal screening working standards of the National Down's Syndrome Screening Programme for England 12 have proposed that by 2007 all women presenting for maternity care before 14 weeks will have to be o¡ered screening by a combination of tests that allows for a detection rate better than 75% at a 3% falsepositive rate, and that screening with a combination of NT and ¢rst trimester biochemistry will achieve this target. Thus, laboratories in the UK will need to consider how to introduce a service including these two biochemical markers. Currently, many UK laboratories perform immunoassay methods on dedicated automated platforms, of which the DPC Immulite 2000 system (Diagnostic Products Corp., Los Angeles, CA, USA) has a signi¢cant market share. Until recently, methods for measuring PAPP-A and free b-hCG were not available on routine laboratory high-throughput immunoassay analysers. With the launch of such methods on the Immulite 2000, it is appropriate and timely to investigate the clinical and analytical performance of such a system for ¢rst trimester screening compared with the system most commonly used for ¢rst trimester screening (70% of users on UKNEQAS) and the one for which there is the greatest clinical experience. 1,7--9 
Methodology
The Clinical Biochemistry Department at Harold Wood Hospital has used two Immulite 2000 instruments to perform all of its Endocrinology testing for the past six years and therefore has considerable experience of the analysers. The DPC free b-hCG and PAPP-A assays were made available by DPC for this evaluation. All assays were run according to the manufacturer's protocols on one Immulite 2000 instrument. A series of two kit lots of reagents were used for both analytes. These were kit lots 106 and 201 for free b-hCG and kit lots 102 and 103 for PAPP-A. The assays were run on a total of 13 separate and non-consecutive days between the period 10 October 2003 and 29 November 2003. The period covered four calibrations for each analyte. In order to control each assay, control samples from the two-level DPC Control Modules (LPCCM Lot 0001and LFBCM Lot 0006) were run along side patient's samples and control samples used in the routine Kryptor free b-hCG and PAPP-A assays. The DPC free b-hCG controls were lyophilized human free b-hCG in a human serumbased matrix, while the PAPP-A controls were liquid PAPP-A of unknown origin in a non-human serum matrix. The Kryptor controls were both lyophilized human serum-based controls.
To assess within-run assay precision, 20 replicates of each control were analysed sequentially. To assess between-day precision, one aliquot of each control level was run in singlicate along with each batch of samples. For comparison purposes, the between-day precision was also compared with that for the Kryptor using the Kryptor controls run over the same analysis period.
For comparison purposes and to establish indicative medians at11--14 weeks of gestation, a series of samples (n ¼ 813) from the routine ¢rst trimester workload of the department were analysed with both the DPC methods and the department's routine screening system --the Brahms Kryptor (Brahms AG, Berlin, Germany). Samples were analysed either on the same day on both systems or within 48 h of being analysed on the Kryptor system. All samples were kept at 41C before analysis and between analysis on each system. The stability of free b-hCG over this period and under such storage conditions is well documented 13 and PAPP-A is similarly very stable (Spencer 1998, unpublished) .
To compare the performance of the DPC system with that of the Kryptor, a series of 20 previously distributed, fresh samples were obtained from the UKNEQAS Pilot First Trimester EQA scheme. The results from these samples were compared with the ALTM and the Kryptor method mean.
To check dilutional linearity, two samples with high free b-hCG or high PAPP-A levels were diluted with varying amounts of a male serum. The percentage recovery of the material added to the male serum was calculated. Additionally, various amounts of a recombinant PAPP-A preparation 14 were added to a male serum to assess recovery and the samples analysed in the DPC system, the Kryptor system and in the AutoDel¢a system (Perkin-Elmer, Finland).
To assess the potential clinical performance of the DPC assays when used to screen for Down's syndrome in the ¢rst trimester of pregnancy, a series of maternal serum samples from women carrying a fetus with Down's syndrome were retrieved from frozen storage (À401C) and analysed on the DPC system. All samples had been collected as part of routine ¢rst trimester screening of women of all maternal ages in our centre over the past ¢ve years. Aliquots of serum had been stored in 250 mL amounts and had not previously been thawed out once frozen. Of the 60 cases, nine had resulted in a live-born Down's syndrome baby: six of these nine cases had been missed (10%) by our current screening programme of NT and ¢rst trimester biochemistry, two cases declined invasive testing and one case opted for no termination of pregnancy.
To compare clinical performance, the free b-hCG and PAPP-A results were converted to MoMs using the medians established in this study. The individual marker concentrations were compared with the measured value with the Kryptor and the MoMs were also compared between the two systems. The population distribution parameters were established for the two markers and compared with those established in a larger series. 1 Standard statistical modelling techniques 1, 15 were used with the observed population distribution parameters, and the a priori maternal age risk at 12 weeks 16 to calculate the expected detection rate at a ¢xed 5% false-positive rate using a maternal age distribution of pregnancies in England and Wales from 2001. 17 
Results
Within-run and between-day precision Table 1 shows the within-run and between-day precision data for the two analytes and the DPC and Kryptor controls. The mean values for the Kryptor free b-hCG controls run on the Immulite 2000 show very similar values, but the Kryptor PAPP-A controls have much higher values (some 3.8 times higher), indicating some di¡erence in the reactivity between the two systems or some sample matrix e¡ect. It is of note that the DPC control material, unlike the Kryptor material, was a non-human serum matrix. The precision of the DPC Immulite system is poorer than that routinely observed with the Kryptor system in our laboratory. Previous studies in our laboratory have shown the within-run coe⁄cient of variation (CV) to be less than 1% across the assay range 18 and less than 3% between-day. 19 Over the evaluation period, the corresponding between-day performance on DPC was 2.8%, 2.4% and 2.6 % for the three free b-hCG controls, and 2.9%, 2.5% and 2.1 % for the three PAPP-A controls.
The impact of these sizes of di¡erence in within-run and between-day precision on the risk estimates has been published previously. 19 The CV of a risk of 1 in 250 is likely to be of the order of 15% rather than the 7% observed with Kryptor.
Dilution recovery
Dilution recovery was assessed by taking one high and one medium-range sample and serially diluting each in normal male serum. Each dilution was analysed in quadruplicate. The results are shown tabulated in Table 2 and show acceptable linearity of dilution with correlation coe⁄cients of better than 0.999.
When recovery was assessed by adding various amounts of recombinant PAPP-A to a male serum, the DPC system showed a signi¢cant (Table 3 ) over-recovery of PAPP-A compared with the same samples run on the Kryptor or the AutoDel¢a. Although there is no International Standard for PAPP-A, the availability of recombinant material is being considered as a possible candidate standard. Clearly, the behaviour of the recombinant material in the DPC system is signi¢cantly di¡erent from either of the two major suppliers of PAPP-A assays. Table 1 . Within-run and between-day precision of free b-hCG (fbeta) and PAPP-A (pa) on Immulite 2000 for the DPC controls (dpc1 and dpc2) and the Kryptor controls (gm1, gm2 and gm3) 
Performance with EQA samples
Twenty fresh samples that had been previously distributed in the UKNEQAS Pilot First Trimester Down's Syndrome Screening EQA programme were provided by the scheme organizer. Each sample was analysed using the Immulite system for free b-hCG and PAPP-A and the results compared with the quoted ALTM and the method mean for Kryptor using data supplied by the scheme organizer. The results indicated a small but not signi¢cant positive bias against the ALTM for free b-hCG (2.05%), which is removed when this is compared with the Kryptor mean (0.07%). For PAPP-A, the results indicate a signi¢cant positive bias against the ALTM (20.65%), which is reduced but not removed by comparison with the Kryptor mean (11.10%). The correlation against the Kryptor mean shows a correlation coe⁄cient of 0.99 for free b-hCG and a slope of 0.964. For PAPP-A, the correlation with the Kryptor shows a slope of 0.889 with a correlation coe⁄cient of 0.98. The ALTM for PAPP-A on the UKNEQAS scheme is a little insecure since in the absence of an international standard it is not possible to fully validate the UKNE-QAS ALTM target. Furthermore, the ALTM may be in-£uenced by the known 20% bias of the Perkin-Elmer Del¢a system 20 compared with the Kryptor system.We therefore made an additional comparison to the Kryptor mean. However, a di¡erence of 10% is probably greater than one would have expected given that the assay is said to be calibrated against the Kryptor. Further assessment against routine samples should enable a better assessment of whether this is 'true' bias or related only to EQA samples. First trimester maternal serum screening for Down's syndrome concentration-related negative bias evident above free b-hCG concentrations of 50--60 IU/L. Figure 3 compares the PAPP-A results obtained by the Immulite 2000 and the Kryptor methods (r ¼ 0.966). Of the 813 samples, 20 results on the Immu-lite 2000 were above the top of the range of the assay. The slope and correlation of the two assays was di¡erent from that observed with the smaller UKNEQAS data-set, which showed a positive bias of11% compared with the 12% negative bias seen in this larger patient series. When the data were examined as a bias plot, there was no signi¢cant concentration-related bias evident.
Comparison with normal patients' samples

Establishing gestational age-specific medians in unaffected pregnancies
The median free b-hCG and PAPP-A at each completed week of gestation in the ¢rst trimester are shown in Table 4 , along with the median gestation of the samples in each group (as decimal weeks). 
Distribution of normal MoM results in log domain
In order for biochemical markers to be used e¡ectively in the Gaussian Model for risk assessment, it must be demonstrated that such markers follow a Gaussian distribution (usually after log transformation). The frequency distribution for free b-hCG MoM after log transformation was shown to ¢t a Gaussian distribution. The median MoM was 1.00 with a log10 mean of 0.000 (95%CI À 0.018--0.017) and a standard deviation of 0.2445. The frequency distribution for PAPP-A MoM after log transformation was also shown to be a good ¢t to a Gaussian distribution. The median MoM was 1.00, with a log10 mean of 0.001 (CI --0.015 to 0.017) and a standard deviation of 0.2298. The standard deviation of the log MoMs for both markers is slightly smaller than that seen in a previously published series 1 but is similar to that seen in long-term routine use with the Kryptor.
The ¢nal parameter of the normal data-set required for risk calculation is the correlation coe⁄cient between the two marker levels and this was 0.2934. This is consistent with but slightly higher than the correlation coe⁄cient found in other studies, which is of the order of 0.17. 1 For PAPP-A, the slope and correlation of the two assays was better than that observed with the smaller UKNEQAS data-set and the normal patient's samples. When the data were examined as a bias plot, as previously with the normal samples, there was no evident concentration-related bias. Of the 60 samples, two results on the Immulite 2000 were above the top of the range of the assay for free b-hCG. The slope and correlation of the two assays was slightly poorer than that observed with the smaller UKNEQAS data-set and the normal pregnancy set. When the data were examined as a bias plot (Figure 9 ), it again became obvious that there is a signi¢cant concentration-related bias evident above free b-hCG concentrations of 100 IU/L.
Comparison with patients' samples with a Down's syndrome fetus
A further assessment of comparability between the two methods was performed after conversion of the analytical results to MoM based on the previous formulae and the gestational age when the sample was taken. The results for free b-hCG show a signi¢cant worsening of the correlation when converted to MoMs (Immulite ¼ 0.7742 Â Kryptor þ 0.3682, r ¼ 0.965). The bias plot showed the presence of increasing bias with MoM --presumably re£ecting the increased bias observed as concentration increases. The results for PAPP-A show a slightly worsening of agreement of results on conversion to MoM (Immulite ¼1.2189 Â Kryptor þ 0.0607, r ¼ 0.982) and a signi¢cant positive slope ( Figure 10 ). The bias plot ( Figure 11 ) showed some signi¢cant positive MoM-related bias.
When the frequency distributions for free b-hCG MoM and PAPP-A MoM after log transformation were examined, the standard linearity plot indicated that the distributions ¢tted a Gaussian form. The standard deviation of the distributions was 0.2431 for free b-hCG and 0.2977 for PAPP-A. The standard deviations of the log MoMs are similar to those observed in other studies, with those for free b-hCG being slightly smaller. The median MoM PAPP-A observed in the Down's syndrome population was 0.62 using the Immulite 2000 assay (mean log10 ¼ À0.173 [95% CI À0.250 to À0.097]). This is signi¢cantly higher than the equivalent median MoM PAPP-A of 0.47 observed in the same samples analysed using Kryptor. Statistical analysis using paired t-test of equal variance shows the results to be signi¢cantly di¡erent (P ¼ 0.025). For free b-hCG, the median MoM in the Down's syndrome population was 1.703 (mean log10 ¼ 0.251 [CI 0.189--0.313]) by Immulite 2000 and 1.698 by Kryptor in the same sample series. Statistical analysis using paired t-test of equal variance shows the results to be not signi¢cantly di¡erent (P ¼ 0.67). The correlation coe⁄cient of the log10 MoM of the two markers was 0.198. This is consistent with the correlation coe⁄cient found in larger studies which is of the order of 0.216. 1 Expected detection rate and false-positive rate in population screening when using the Immulite 2000 free b-hCG and PAPP-A assays In order to assess how the Immulite 2000 assays may perform in clinical practice given the population parameters derived for the normal population and the Down's syndrome population, it is necessary to use standard population-modelling techniques. The results of this modelling exercise indicate that at a 5% falsepositive rate the DPC Immulite PAPP-A and free b-hCG methods can expect, based on this study, to give a detection rate of 58%. In comparison, using the same sample series and the results from Kryptor to generate population parameters, the same modelling exercise produces a detection rate of 62% for a 5% false-positive rate. This again compares with the detection rate of 67% predicted from population parameters derived from a much larger series of 210 cases with Down's syndrome. 1 The reasons for these di¡erences relate mainly to the di¡erences in median MoM seen in the various studies for the two markers. In the larger series, the median MoM free b-hCG was 2.15, which is similar to the summary of the world published series of 1.98 MoM, 21 both being higher than the median of 1.7 in this smaller series for either Immulite or Kryptor. In the larger series, the median MoM PAPP-A was 0.51 MoM, which is similar to the summary of the world published series of 0.45. 21 The median MoM as measured by of 0.47 Kryptor is consistent with the larger series and the world summary; however, the median of 0.62 observed with the Immulite assay is signi¢cantly higher, resulting in the lower predicted detection rate.
In the ¢rst trimester, it is highly unlikely that biochemical markers alone would be used in screening populations. In practice, combination with the ultrasonographic marker NT would occur. 1,7--10 The impact of the above-described di¡erences in detection rate would be signi¢cantly reduced because of the greater contribution of NT to detection rates. Mathematical modelling would predict that using the Fetal Medicine Foundation NTdata 1 along with the Immulite 2000 observed population parameters in this study would result in detection rates of the order of 85% compared with the 89% observed using Kryptor in the largest published series. 1 By comparison, use of the same samples and the Kryptor data would have only resulted in a 2% lower-than-expected detection rate.
Discussion
The within-run and between-day precision of the Immulite 2000 free b-hCG and PAPP-A assays were considerably worse than those obtained with existing automated assays for these analytes. The consequence of this level of precision performance is that the CV of the risk at a mean risk of 1 in 250 is likely to be of the order of 15% compared with levels of 7% achievable with platforms such as the Kryptor, and this may compromise clinical performance when screening using this platform. 19 EQA sample testing indicated no significant bias against the ALTM or Kryptor method mean for free b-hCG, but a signi¢cant positive bias of 20% against the ALTM for PAPP-A and a positive bias of 11% against the Kryptor method mean. Although the Kryptor method dominates the ALTM for PAPP-A, the lack of availability of an international reference preparation makes it impossible to challenge any of the commercial assays available for PAPP-A with recovery experiments. However, recovery using a candidate recombinant material being considered as a possible standard suggests that the Immulite 2000 assay may not be recognizing the material in the same way as other analytical platforms. Also of some concern is the fact that commercially available controls for PAPP-A from another manufacturer also show over-recovery of PAPP-A. Normal patient's samples showed a concentrationrelated negative bias for free b-hCG against the Kryptor with signi¢cant bias above 50 IU/L. Conversion of free b-hCG results to MoM produced a worsening of the correlation with Kryptor with again a signi¢cant MoMrelated negative bias beyond 2 MoM. Normal patients' samples showed a slope of less than 0.9 for PAPP-A against the Kryptor, with the bias being constant across the concentration range, but EQA samples showed a positive bias. Conversion of PAPP-A results to MoM showed a signi¢cant improvement of the correlation with Kryptor with no observed bias. Correlation of free b-hCG concentration in cases with Down's syndrome showed a poorer agreement with Kryptor than in the una¡ected pregnancies. A concentration-related negative bias was evident above 100 IU/L. After conversion to MoM, the free b-hCG showed a signi¢cant worsening of agreement with Kryptor and a negative bias above 2 MoM. The median MoM of 1.703 for free b-hCG was very close to the 1.698 observed for the same series with Kryptor. The SD of the log10 transformed MoMs was slightly smaller than observed in other studies with Kryptor. Correlation of PAPP-A concentration in cases with Down's syndrome showed much greater agreement with Kryptor than in the una¡ected pregnancies. No concentration-related bias was evident. After conversion to MoM, the PAPP-A data in the Down's syndrome group showed a slight worsening of agreement with Kryptor and a positive MoM-related bias. The median MoM of 0.62 for PAPP-A was signi¢cantly di¡erent (P ¼ 0.025) from the 0.47 observed with Kryptor. The SD of the log10 transformed MoMs was similar to that observed in other studies with Kryptor. The consequence of this di¡erence in PAPP-A, which may be related to antibody speci¢city, is that modelled detection rates showed that the Immulite 2000 is likely to detect 58% of cases at a 5% false-positive rate, compared with 62% in this same series using the Kryptor. The expected detection rate from a larger series of over 200 cases indicates expected results of 67% at a 5% false-positive rate. 1 The potential decreased detection using the Immulite 2000 assays would be expected to diminish when combined with NT. Detection using NT and the biochemical markers measured on Kryptor have been shown to be 89--90% in retrospective modelling and in prospective practice. 1,7--9 The Immulite 2000 assays could be expected to achieve detection rates of 85% in combination with NT.
This evaluation has shown some concerns regarding the precision of the Immulite 2000 platform in per-forming ¢rst trimester Down's syndrome screening assays, which could impact on clinical performance. The dose-related bias of the free b-hCG assay needs further attention by the manufacturer, as does the bias for PAPP-A. The overall poorer clinical discrimination for PAPP-A is of some concern and this may again impact on clinical performance. Whether the performance in over-recovery of recombinant PAPP-A is a factor here needs further consideration. While laboratories may ¢nd some organizational bene¢t from running ¢rst trimester Down's syndrome-screening on routine highthroughput immunoassay analysers, such as the Immulite 2000, better clinical performance is likely to be achieved with alternative platforms such as the Kryptor, as shown in this comparison. Laboratories considering utilizing the DPC Immulite 2000 assay in ¢rst trimester clinical practice need to carefully consider the ¢ndings of this study.
